clinical trial · NCT05380752

Tecovirimat Intravenous Treatment for Orthopox Virus Exposure

U.S. Army Medical Research and Development Command·—·no longer available

Orthopox Virus InfectionTPOXX IV (Tecovirimat Injection, 10 mg/mL)

brief summary

* To provide a therapeutic option for patients not able to take the oral formulation of TPOXX (e.g., cannot swallow, vomiting) and who have confirmed or suspected (based on clinical signs and symptoms with known exposure while laboratory confirmation may be pending) orthopox virus infections OR who have a significant vaccinia adverse reaction (as defined in the protocol) resulting from vaccinia vaccination, secondary transmission, or other exposure; * To collect data on the safety of TPOXX IV (tecovirimat injection, 10 mg/mL).

started

—

primary completion

—

completion

—

last updated

Mar 10, 2025

official title

EXPANDED ACCESS PROTOCOL FOR TREATMENT OF INDIVIDUALS FOLLOWING EXPOSURE TO ORTHOPOX VIRUSES WITH TPOXX IV (TECOVIRIMAT INJECTION, 10 mg/mL)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol